Suppr超能文献

S100A12 在甲状腺乳头状癌中是一种很有前途的生物标志物。

S100A12 is a promising biomarker in papillary thyroid cancer.

机构信息

Department of anatomy, Shenyang Medical College, Huanggu District, Shenyang City, Liaoning Province, 110034, P.R. China.

Department of Radiology, The Second Affiliated Hospital of Shenyang Medical College, Shenyang City, Liaoning Province, 110035, P.R. China.

出版信息

Sci Rep. 2020 Feb 3;10(1):1724. doi: 10.1038/s41598-020-58534-1.

Abstract

S100A12 belongs to the S100 family and acts as a vital regulator in different types of tumors. However, the function of S100A12 in thyroid carcinoma has not yet been investigated. In this study, we analyzed the expression of S100A12 in human papillary thyroid cancer (PTC) samples and two PTC cell lines. In addition, we explored the effects of S100A12 on PTC cell progression in vitro and in vivo. Our results showed that S100A12 was significantly upregulated in PTC specimens. Moreover, silencing S100A12 markedly inhibited PTC cell proliferation, migration, invasion and cell cycle progression. In addition, knockdown of S100A12 significantly reduced the expression of CyclinD1, CDK4 and p-ERK in PTC cells. An in vivo study also showed that silencing S100A12 dramatically suppressed tumor cell growth and decreased Ki67 expression in a xenograft mouse model. This study provides novel evidence that S100A12 serves as an oncogene in PTC. Knockdown of S100A12 suppressed PTC cell proliferation, migration, and invasion and induced G0/G1 phase arrest via the inhibition of the ERK signaling pathway. Therefore, S100A12 may be a potent therapeutic target for PTC.

摘要

S100A12 属于 S100 家族,在多种类型的肿瘤中充当重要的调节因子。然而,S100A12 在甲状腺癌中的功能尚未被研究。在本研究中,我们分析了 S100A12 在人甲状腺乳头状癌(PTC)样本和两种 PTC 细胞系中的表达。此外,我们还探讨了 S100A12 对 PTC 细胞在体外和体内进展的影响。我们的结果表明,S100A12 在 PTC 标本中显著上调。此外,沉默 S100A12 明显抑制 PTC 细胞增殖、迁移、侵袭和细胞周期进程。此外,S100A12 的敲低显著降低了 PTC 细胞中细胞周期蛋白 D1(CyclinD1)、细胞周期蛋白依赖性激酶 4(CDK4)和磷酸化 ERK(p-ERK)的表达。一项体内研究还表明,沉默 S100A12 可显著抑制肿瘤细胞生长,并降低异种移植小鼠模型中 Ki67 的表达。本研究提供了新的证据,表明 S100A12 作为 PTC 的致癌基因。S100A12 的敲低通过抑制 ERK 信号通路,抑制 PTC 细胞增殖、迁移和侵袭,并诱导 G0/G1 期阻滞。因此,S100A12 可能是 PTC 的一个有潜力的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ac/6997206/40dde8db8822/41598_2020_58534_Fig1_HTML.jpg

相似文献

1
S100A12 is a promising biomarker in papillary thyroid cancer.
Sci Rep. 2020 Feb 3;10(1):1724. doi: 10.1038/s41598-020-58534-1.
2
BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Oncotarget. 2017 Jan 3;8(1):238-247. doi: 10.18632/oncotarget.10825.
3
LncRNA HOTTIP promotes papillary thyroid carcinoma cell proliferation, invasion and migration by regulating miR-637.
Int J Biochem Cell Biol. 2018 May;98:1-9. doi: 10.1016/j.biocel.2018.02.013. Epub 2018 Feb 21.
4
SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.
Oncogene. 2020 Mar;39(13):2658-2675. doi: 10.1038/s41388-020-1181-z. Epub 2020 Jan 31.
5
IL-34 is a potential biomarker for the treatment of papillary thyroid cancer.
J Clin Lab Anal. 2020 Aug;34(8):e23335. doi: 10.1002/jcla.23335. Epub 2020 Jun 23.
10
PDLIM5 identified by label-free quantitative proteomics as a potential novel biomarker of papillary thyroid carcinoma.
Biochem Biophys Res Commun. 2018 May 5;499(2):338-344. doi: 10.1016/j.bbrc.2018.03.159. Epub 2018 Mar 24.

引用本文的文献

1
Identification of a tumor microenvironment-related gene signature for predicting prognosis in patients with gastric cancer.
Medicine (Baltimore). 2025 Aug 29;104(35):e44032. doi: 10.1097/MD.0000000000044032.
2
Orosomucoid 1 interacts with S100A12 and activates ERK signalling to expedite the advancement of bladder cancer.
Cell Adh Migr. 2025 Dec;19(1):1-11. doi: 10.1080/19336918.2024.2434209. Epub 2024 Dec 7.
3
overexpression stimulates cell proliferation and is predictive of poor outcome in ovarian cancer.
Transl Cancer Res. 2024 Oct 31;13(10):5265-5277. doi: 10.21037/tcr-24-430. Epub 2024 Oct 21.
6
9
S100 proteins in head and neck squamous cell carcinoma (Review).
Oncol Lett. 2023 Jul 6;26(2):362. doi: 10.3892/ol.2023.13948. eCollection 2023 Aug.

本文引用的文献

2
Blocking the ERK1/2 signal pathway can inhibit S100A12 induced human aortic smooth muscle cells damage.
Cell Biol Int. 2017 Dec;41(12):1307-1315. doi: 10.1002/cbin.10840. Epub 2017 Sep 5.
3
Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
J Laryngol Otol. 2016 May;130(S2):S150-S160. doi: 10.1017/S0022215116000578.
4
Therapeutic options in papillary thyroid carcinoma: current guidelines and future perspectives.
Future Oncol. 2016 Nov;12(22):2603-2613. doi: 10.2217/fon-2016-0171. Epub 2016 Jul 8.
5
Treating cancer with selective CDK4/6 inhibitors.
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30. doi: 10.1038/nrclinonc.2016.26. Epub 2016 Mar 31.
7
What Is the Optimal Treatment of Papillary Thyroid Cancer?
Adv Surg. 2015;49:79-93. doi: 10.1016/j.yasu.2015.03.007. Epub 2015 May 1.
8
Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins.
Cancer Lett. 2015 Aug 28;365(1):11-22. doi: 10.1016/j.canlet.2015.05.002. Epub 2015 May 8.
10
Targeting RAS-ERK signalling in cancer: promises and challenges.
Nat Rev Drug Discov. 2014 Dec;13(12):928-42. doi: 10.1038/nrd4281.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验